Immunic IncNASDAQ IMUX Stock Report

Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 66 full-time employees. The company went IPO on 2014-04-17. The company is engaged in the clinical development of three orally administered, small molecule programs to address the unmet needs of patients. These include the vidofludimus calcium (IMU-838) program, which is focused on the development of oral formulations of a small molecule inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH); the IMU-935 program, which is focused on an inverse agonist of retinoic acid receptor-related orphan nuclear receptor gamma truncated (RORyt), an immune cell-specific isoform of RORy; and the IMU-856 program, which involves the development of a drug targeting the restoration of intestinal barrier function and regeneration of bowel epithelium. These product candidates are being developed to address diseases such as multiple sclerosis (MS), psoriasis and gastrointestinal diseases.